Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00501735

Recruitment Status : Completed

First Posted : July 16, 2007

Last Update Posted : January 23, 2012

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

BioCryst Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 2010
Actual Study Completion Date :	December 2011
Certification/Extension First Submitted :	January 18, 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Ann Oncol. 2014 Sep;25(9):1807-1812. doi: 10.1093/annonc/mdu231. Epub 2014 Jun 19.

To Top